Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AGNPF save search
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Published: 2021-11-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 14515.38%
H: 0.0%
C: -1.95%
fda lung cancer phase 1 positive cancer phase 2
Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-06-22 (Crawled : 14:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 34.22%
H: 0.0%
C: 0.0%
treatment fibrosis patent
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2024-03-27 (Crawled : 16:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 25.81%
H: 0.0%
C: 0.0%
acquisition pharmaceuticals research program
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-05 (Crawled : 19:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 21.05%
H: 0.0%
C: -4.78%
treatment fda fibrosis pharmaceuticals designation drug
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Published: 2023-11-30 (Crawled : 17:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 12.32%
H: 0.0%
C: 0.0%
patent treat pharmaceuticals grant chinese nash
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 11.11%
H: 1.6%
C: -4.24%
patent pharmaceuticals grant nash
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -4.78%
fda phase 2 als phase 2b positive chronic cough
Algernon Pharmaceuticals Announces Closing of Private Placement
Published: 2023-12-27 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 9.2%
H: 20.51%
C: 15.38%
pharmaceuticals
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Published: 2023-06-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 8.43%
H: 2.28%
C: 2.28%
conference pharmaceuticals phase 2
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 7.95%
H: 45.61%
C: 24.56%
acquisition pharmaceuticals research program
Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 7.69%
H: 12.89%
C: 7.45%
management
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 5.02%
H: 13.06%
C: 11.46%
patent treat pharmaceuticals grant chinese
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
Published: 2022-11-16 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 4.59%
H: 0.39%
C: -6.69%
pharmaceuticals stroke study phase 1
Algernon Pharmaceuticals Announces Private Placement
Published: 2023-12-13 (Crawled : 01:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 3.68%
H: 0.0%
C: -5.92%
pharmaceuticals
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 3.66%
H: 0.36%
C: 0.36%
phase 2
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Published: 2021-12-08 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 3.62%
H: 10.26%
C: 0.87%
phase 2 drug stroke
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 3.21%
H: 29.32%
C: -3.11%
study
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 3.1%
H: 0.94%
C: -3.21%
drug group pharmaceuticals program phase 2
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: -0.93%
pharmaceuticals trial agreement depression study phase 2
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
Published: 2022-06-21 (Crawled : 19:00) - biospace.com/
AGNPF | $0.089 178.69% 22K
|
Health Technology
|
| O: 2.48%
H: 0.0%
C: -6.35%
ongoing phase 2
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.